The agency was originally scheduled to announce its call on Sunday. The company said it hadn’t flagged any issues with the ...
The FDA needs a few more weeks to decide the fate of Moderna's RSV vaccine, the company announced. A decision is now slated ...
The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.
Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for ... t expect major delays from here onwards and FDA should be able ...
米バイオテクノロジー大手 モデルナ は10日、呼吸器合胞体ウイルス(RSV)ワクチンの承認可否に関する米食品医薬品局(FDA)の決定が、「事務的な制約」で先送りされたと明らかにした。
Moderna shares fell in intraday trading Friday as it said the FDA has pushed back its RSV vaccine approval decision until the ...
The Cambridge company said the FDA cited “administrative constraints” in its decision to push ... on its review of the RSV vaccine. “Although regulatory delays are disappointing and usually ...
Moderna announced that the FDA had delayed approval of its RSV vaccine to the end of May due to "administrative constraints" ...
US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to ... get its second product to market. The FDA hasn’t informed Moderna of any issues ...
Moderna (NASDAQ:MRNA) shares are down just over 1% in early Friday trading after the company said the FDA ... RSV vaccine due to "administrative constraints." However, they remain on track for a ...